Celcuity Inc. (NASDAQ:CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

The Food and Drug Administration (FDA) has approved Truqap ™ (capivasertib) in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal ...

We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...

Upgraded Relay Therapeutics to a buy after valuation decline. Read more on RLAY's pipeline progress, financial health, and ...

Find out how to take Fulvestrant(drug) and its dose. Describes the best time to take the drug and precautions if any that should be followed.

Fulvestrant was as effective as anastrozole in terms of time to progression (TTP) (hazard ratio, 0.92; 95% confidence interval [CI], 0.74-1.14; P =.43). Median TTP was 5.4 months with fulvestrant ...

Correspondence Anastrozole and Fulvestrant in Metastatic Breast Cancer Published October 25, 2012 N Engl J Med 2012;367: 1662 - 1664 DOI: 10.1056/NEJMc1210463 ...

The median time to treatment failure was 17.6 months in the fulvestrant arm and 12.7 months in the anastrozole arm, representing an HR of 0.73 (95% CI, 0.54-1.00).

Fulvestrant reduced risk of progression by 20% and extended median progression-free survival beyond anastrozole October 08, 2016 08:00 AM Eastern Daylight Time ...

For fulvestrant to work well, the cells must also be responsive to estrogen, and producing the estrogen receptor ER-alpha. ER-alpha's importance to fulvestrant's anti-estrogenic action had been ...